Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37843
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | CUPPENS, Kristof | - |
dc.contributor.author | Baas, Paul | - |
dc.contributor.author | GEERDENS, Ellen | - |
dc.contributor.author | Cruys, Bert | - |
dc.contributor.author | FROYEN, Guy | - |
dc.contributor.author | Decoster, Lynn | - |
dc.contributor.author | THOMEER, Michiel | - |
dc.contributor.author | MAES, Brigitte | - |
dc.date.accessioned | 2022-08-03T08:14:02Z | - |
dc.date.available | 2022-08-03T08:14:02Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-06-13T14:42:36Z | - |
dc.identifier.citation | Lung cancer, 170 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | http://hdl.handle.net/1942/37843 | - |
dc.description.abstract | Immune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing. | - |
dc.description.sponsorship | Acknowledgments The authors would like to thank Kristine Jinnett and Kirsten Curnow (Illumina, Inc.) for their manuscript preparation assistance. Funding This work was partially supported by the provision of sequencing reagents and sequencing analysis tools by Illumina, Inc | - |
dc.language.iso | en | - |
dc.publisher | - | |
dc.rights | 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | - |
dc.subject.other | HED | - |
dc.subject.other | HLA-I diversity | - |
dc.subject.other | HLA-I evolutionary divergence | - |
dc.subject.other | Non-small cell lung cancer | - |
dc.subject.other | PD-1 immunotherapy | - |
dc.subject.other | TSO500 | - |
dc.subject.other | Tumor mutational burden | - |
dc.title | HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 10 | - |
dc.identifier.spage | 1 | - |
dc.identifier.volume | 170 | - |
local.format.pages | 10 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1016/j.lungcan.2022.05.019 | - |
dc.identifier.pmid | 35689896 | - |
dc.identifier.isi | 000861749300001 | - |
dc.identifier.eissn | 1872-8332 | - |
local.provider.type | PubMed | - |
local.dataset.doi | 10.1016/j.lungcan.2022.05.019 | - |
local.uhasselt.international | yes | - |
item.contributor | CUPPENS, Kristof | - |
item.contributor | Baas, Paul | - |
item.contributor | GEERDENS, Ellen | - |
item.contributor | Cruys, Bert | - |
item.contributor | FROYEN, Guy | - |
item.contributor | Decoster, Lynn | - |
item.contributor | THOMEER, Michiel | - |
item.contributor | MAES, Brigitte | - |
item.fullcitation | CUPPENS, Kristof; Baas, Paul; GEERDENS, Ellen; Cruys, Bert; FROYEN, Guy; Decoster, Lynn; THOMEER, Michiel & MAES, Brigitte (2022) HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. In: Lung cancer, 170. | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
item.validation | ecoom 2023 | - |
crisitem.journal.issn | 0169-5002 | - |
crisitem.journal.eissn | 1872-8332 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0169500222004640-main.pdf | Published version | 3.68 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.